Drugs / ALN-4324
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06845202 | Mar 2025 → Aug 2027 expected | type 2 diabetes mellitus | Alnylam Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07465224 | Jan 2026 → May 2027 expected | type 2 diabetes mellitus | Alnylam Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-02-25 | Alnylam Pharmaceuticals | Results Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day alnylam.com ↗
At R&D Day, Alnylam will present preclinical data that demonstrate the potential for a highly desirable product profile, including approximately 90% knockdown of the target 22 days after a low-dose, subcutaneous injection, and improved insulin sensitivity without weight gain. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-02-25 | Alnylam Pharmaceuticals | Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day alnylam.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-4324 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06845202 ↗ |
| Route | Subcutaneous | “ALN-4324 will be administered subcutaneously (SC)” NCT06845202 ↗ |